NeurAxis announced strong Q1 2025 results, with a 39% revenue increase and expanded payer coverage, while operating loss improved. NeurAxis, Inc. reported a strong first quarter for 2025, with ...

NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children ...

NeurAxis reports 43% revenue growth in Q4 2024, significant advancements in insurance coverage, and FDA approvals for its technologies. NeurAxis, Inc. reported its fourth quarter and fiscal year 2024 ...

CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children ...

The new CPT code reflects the latest efficacious medical care available to patients, facilitating adoption and utilization. The assignment of a Category I CPT® code demonstrates a strong message to ...

CARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

Achieves significant expansion of NeurAxis’ total addressable market Clearance now includes patients aged “8 years and older” Expanded age indication will utilize the upcoming January 1 st, 2026, ...

CARMEL, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address ...

Brian Carrico is the President and Chief Executive Officer of NeurAxis, Inc., a growth stage med-tech company addressing chronic and debilitating conditions in children. Mr. Carrico also serves as a ...

NeurAxis Inc NRXS highlighted A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients with Post-Concussion Syndrome (PCS), a randomized, ...